title: gender-specific outcome after paclitaxel-eluting stent implantation in japanese patients with coronary artery disease--sub-analysis of the Japan TAXUS Express2 post-marketing survey.
abstract: BACKGROUND
  Although previous randomized and non-randomized studies have demonstrated the safety and efficacy of paclitaxel-eluting stents (PES), a higher revascularization rate has been reported in women than in men. A sub-analysis of the TAXUS Japan Post-market Surveillance Study (TAXUS-PMS) was done to assess the influence of gender on clinical outcome.
  
  
  RESULTS
  A total of 2,132 PES-treated Japanese patients (women, n=551) from this registry were analyzed. Subjects were stratified by gender to compare 1-year clinical outcome. PES-treated women were older and more likely to have insulin-treated diabetes and hypertension. In contrast, PES-treated men were more likely to be smokers, have a previous history of myocardial infarction, and lower ejection fraction. While cardiac death, myocardial infarction and stent thrombosis were similar between men and women, major cardiac events tended to be lower in women than in men (6.4% vs. 8.8%, P=0.08). Although women had significantly smaller reference vessel size (2.46±0.53 mm vs. 2.59±0.60 mm, P<0.0001), the restenosis rate tended to be lower in women than in men (11.5% vs. 14.8%, P=0.11). Subsequently, the target lesion revascularization rate was significantly lower in women than in men (4.2% vs. 6.5%, P<0.05).
  
  
  CONCLUSIONS
  Despite a higher risk profile, Japanese women treated with PES did not have a higher rate of repeat revascularization or major adverse clinical outcome than PES-treated men at 1 year.
authors: Division of Cardiology, Kawasaki Medical School, Matsushima, Kurashiki 701-0192, Japan. hokura@fides.dti.ne.jp
authors: Hiroyuki
authors: H
authors: Okura
authors: Masato
authors: M
authors: Nakamura
authors: Jun-Ichi
authors: J
authors: Kotani
authors: Ken
authors: K
authors: Kozuma
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D044466:Asian People; D003643:Death; D054855:Drug-Eluting Stents; D005260:Female; D006083:Graft Occlusion, Vascular; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D017239:Paclitaxel / Q000494:pharmacology*; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012727:Sex Characteristics; D012737:Sex Factors; D013997:Time Factors
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel